Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Rule 2.9 Announcement

5 Feb 2026 07:00

RNS Number : 7874R
Oxford Biomedica PLC
05 February 2026
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

FOR IMMEDIATE RELEASE

 

5 February 2026

Oxford Biomedica plc ("OXB" or the "Company")

Rule 2.9 Announcement

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers (the "Code"), the Company confirms that, as at close of business on 4 February 2026, its issued share capital consisted of 120,852,814 ordinary shares of £0.50 each, each carrying one vote ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

The International Securities Identification Number for the Ordinary Shares is GB00BDFBVT43. The Company's Legal Entity Identifier is 213800S1GVQNXQ15K851.

Enquiries:

Oxford Biomedica plc:

+44 (0) 1865 783 000

Lucy Crabtree - Chief Financial Officer

 

 

Evercore Partners International LLP (Financial Adviser to OXB)

+44 (0) 20 7653 6000

Julian Oakley

Simon Elliott

Wladimir Wallaert

Harrison George

 

 

Jefferies International Limited (Financial Adviser and Corporate Broker to OXB)

+44 (0) 20 7029 8000

Philip Yates

Sam Barnett

Gil Bar-Nahum

William Brown

 

 

ICR Healthcare:

+44 (0) 20 3709 5700

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

IMPORTANT NOTICES

Evercore Partners International LLP ("Evercore"), which is authorised and regulated by the Financial Conduct Authority ("FCA") in the UK, is acting exclusively as financial adviser to OXB and no one else in connection with the matters described in this announcement and will not be responsible to anyone other than OXB for providing the protections afforded to clients of Evercore nor for providing advice in connection with the matters referred to herein. Neither Evercore nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Evercore in connection with this announcement, any statement contained herein, any offer or otherwise. Apart from the responsibilities and liabilities, if any, which may be imposed on Evercore by the Financial Services and Markets Act 2000, or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, neither Evercore nor any of its affiliates accepts any responsibility or liability whatsoever for the contents of this announcement, and no representation, express or implied, is made by it, or purported to be made on its behalf, in relation to the contents of this announcement, including its accuracy, completeness or verification of any other statement made or purported to be made by it, or on its behalf, in connection with OXB or the matters described in this announcement. To the fullest extent permitted by applicable law, Evercore and its affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement, or any statement contained herein.

Jefferies International Limited ("Jefferies"), which is authorised and regulated by the FCA in the UK, is acting exclusively as financial adviser to OXB and no one else in connection with the matters described in this announcement and will not regard any other person as its client in relation to the matters in this announcement and will not be responsible to anyone other than OXB for providing the protections afforded to clients of Jefferies nor for providing advice in relation to any matter referred to in this announcement. Neither Jefferies nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Jefferies in connection with this announcement, any statement contained herein or otherwise.

The person responsible for arranging for the release of this announcement on behalf of OXB is Natalie Walter, Chief Legal Officer and Company Secretary.

DISCLOSURE REQUIREMENTS OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")

Under Rule 8.3(a) of the Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by not later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by not later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by not later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of the Code).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTUSSURNAUURUR
Date   Source Headline
25th Mar 20225:15 pmRNSHolding(s) in Company
21st Mar 202210:44 amRNSLong Term Incentive Plan Option Grant
15th Mar 202211:25 amRNSHolding(s) in Company
15th Mar 20229:39 amRNSHolding(s) in Company
11th Mar 20224:51 pmRNSHolding(s) in Company
11th Mar 20229:01 amRNSAdmission of Conditional Placing Shares
10th Mar 20225:32 pmRNSCompletion of Transaction
9th Mar 202211:42 amRNSDirector Declaration
8th Mar 20223:54 pmRNSResult of General Meeting
1st Mar 20229:52 amRNSTotal Voting Rights
16th Feb 202211:41 amRNSPublication of Circular & Notice of GM
4th Feb 20228:22 amRNSAdmission of Firm Placing Shares
1st Feb 20229:06 amRNSTotal Voting Rights
1st Feb 20227:00 amRNSUpdate to agreement with Sio Gene Therapies
31st Jan 202211:21 amRNSMarket Share Purchase
28th Jan 20225:59 pmRNSResult of Placing and PrimaryBid offer
28th Jan 20222:04 pmRNSHoldings in Company
28th Jan 20227:38 amRNSRetail offer by PrimaryBid
28th Jan 20227:24 amRNSUS Agreement and Proposed Placing of Shares
17th Jan 20227:00 amRNSJohn Dawson to retire from Oxford Biomedica
5th Jan 20227:00 amRNSOxford Biomedica Agreement with Cabaletta Bio
4th Jan 202211:07 amRNSBlock listing Return
4th Jan 202210:32 amRNSTotal Voting Rights
4th Jan 20227:00 amRNSJohn Dawson awarded CBE in New Year Honours List
14th Dec 20217:00 amRNSBoard Appointment
13th Dec 20217:00 amRNSOxford Biomedica Updates Lentiviral Agreement
13th Dec 20217:00 amRNSOxford Biomedica Signs Agreement with Arcellx
1st Dec 20219:49 amRNSTotal Voting Rights
1st Nov 202110:08 amRNSLong Term Incentive Plan Option Grant
1st Nov 202110:02 amRNSTotal Voting Rights
19th Oct 20217:00 amRNSBoehringer Ingelheim Exercises Option
1st Oct 20219:51 amRNSTotal Voting Rights
29th Sep 20215:54 pmRNSHolding(s) in Company
29th Sep 20215:36 pmRNSDirectors Dealings / Market Share Purchases
28th Sep 20214:48 pmRNSHolding(s) in Company
28th Sep 202110:01 amRNSTotal Voting Rights
22nd Sep 20217:38 amRNSStrategic investment by Serum Life Sciences
22nd Sep 20217:00 amRNSInterim Results
1st Sep 202110:48 amRNSTotal Voting Rights
1st Sep 20217:00 amRNSNotice of Interim Results
3rd Aug 20212:20 pmRNSLTIP Option Grant
2nd Aug 202111:16 amRNSTotal Voting Rights
15th Jul 20217:00 amRNSNon-Executive Director Appointment
6th Jul 20213:10 pmRNSDirector/PDMR Shareholding
1st Jul 202111:35 amRNSBlock listing Return
1st Jul 202110:43 amRNSTotal Voting Rights
24th Jun 20211:05 pmRNSDirectors Dealings / Market Share Purchases
9th Jun 202110:36 amRNSHolding(s) in Company
8th Jun 20212:32 pmRNSGrant of options
1st Jun 202110:13 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.